Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jul 16.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2020 Oct 20;30(1):22–29. doi: 10.1158/1055-9965.EPI-20-1177

Table 1.

Average incidence rates of CIN2+ and CIN3+ detection over 10-year follow-up

		CIN2+			CIN3+
	P-Ys	Cases	IR^a	95% CI	Cases	IR^a	95% CI
Overall	39699.5	20	0.50	(0.31 to 0.78)	7	0.18	(0.07 to 0.36)
Age group^b
25–34	6065.0	6	0.99	(0.36 to 2.15)	2	0.33	(0.04 to 1.19)
35–44	12467.8	6	0.48	(0.18 to 1.05)	1	0.08	(0.00 to 0.45)
45–54	13397.7	6	0.45	(0.16 to 0.97)	2	0.15	(0.02 to 0.54)
55–65	7769.0	2	0.26	(0.03 to 0.93)	2	0.26	(0.03 to 0.93)
Age group^b
25–44	18532.8	12	0.65	(0.33 to 1.13)	3	0.16	(0.03 to 0.47)
45–65	21166.7	8	0.38	(0.16 to 0.74)	4	0.19	(0.05 to 0.48)

^a

Rates per 1000 person-years (P-Ys)

^b

Age groups consider age at baseline entry into FOCAL trial